Gang Zhao

Gang Zhao

Auto-generated profile, based on publicly available information

Gang Zhao

Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2025 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
ZDZiyi Dong
Ziyi Dong
RZRan Zuo
Ran Zuo
YGYaoyang Guo
Yaoyang Guo
XWXinyi Wen
Xinyi Wen
GZGang Zhao
Gang Zhao
ZJzhansheng jiang
zhansheng jiang
Background: The impact of STK11/KEAP1 co-mutations on the efficacy of immunotherapy in patients with SMARCA4-mutant advanced non-small cell lung cancer (NSCLC) remains incompletely understood. Our aim was to investigate the effects of STK11/KEAP1 co-mutations on the clinical prognosis of patients with SMARCA4-mutant advanced NSCLC receiving immunotherapy. Methods: We obtained 2,098 patients with stage IIIB–IV NSCLC from the cBioPortal database. Patients harboring EGFR, ALK, ROS1 and RET mutations were excluded. The impacts of SMARCA4 and STK11/KEAP1 co-mutations on the efficacy of chemoimmunotherapy were analyzed, along with their associations with tumor mutational burden (TMB), programmed cell death ligand 1 (PD-L1) expression, and patient prognosis. Results: Among 2,098 patients with NSCLC, SMARCA4-mutant patients accounted for 7.7% (162/2,098), and wild-type patients accounted for 92.3% (1,936/2,098). SMARCA4 mutations are more common in elderly patients, smokers, and patients with adrenal metastasis. Compared with SMARCA4 wild-type patients, SMARCA4-mutant patients had significantly greater TMB (P<0.001) and poorer median overall survival (mOS) (10.6 vs. 17.5 months, P<0.001). Further analysis revealed that patients with SMARCA4 class I alterations had significantly shorter mOS (8.7 vs. 14.1 months, P=0.008) and median first-line treatment progression-free survival (mPFS1) (3.7 vs. 6.6 months, P=0.003) than those with class II alterations. Multivariate regression analysis confirmed that SMARCA4 mutations significantly increased the risk of death [hazard ratio (HR) =1.329, 95% confidence interval (CI): 1.106–1.596, P=0.002]. Compared with chemotherapy, chemoimmunotherapy significantly prolonged mPFS1 (5.6 vs. 3.9 months, P=0.01) but not mOS (10.8 vs. 9.5 months, P=0.91) in patients with SMARCA4 mutations. Among patients receiving first-line chemoimmunotherapy, TMB levels had no significant effect on mPFS1 (5.6 vs. 6.6 months, P=0.83) or mOS (8.5 vs. 10.8 months, P=0.38), but PD-L1-positive patients had significantly longer mPFS1 (8.3 vs. 5.1 months, P=0.02) and mOS (18.9 vs. 9.3 months, P=0.03). SMARCA4 and STK11/KEAP1 co-mutations were not significantly correlated with TMB (P=0.85) or PD-L1 expression (P=0.08). However, the patients with SMARCA4 and STK11/KEAP1 co-mutations had significantly shorter mPFS1 (4.5 vs. 13.3 months, P<0.001) and mOS (8.7 vs. 20.1 months, P=0.005) in the chemoimmunotherapy group. Among SMARCA4-mutant patients, those without STK11/KEAP1 co-mutations derived longer mPFS1 (13.3 vs. 5.6 months, P=0.01) benefits from immunotherapy. In contrast, this benefit markedly reduced mPFS1 (4.5 vs. 2.9 months, P=0.16) in patients with STK11/KEAP1 co-mutations, suggesting that STK11/KEAP1 may affect the immunological efficacy in patients with SMARCA4 mutations. Conclusions: Patients with SMARCA4-mutant NSCLC can benefit from chemoimmunotherapy. However, STK11/KEAP1 co-mutations were associated with poorer prognosis and reduced immunotherapy efficacy in SMARCA4-mutant advanced NSCLC. Moreover, STK11/KEAP1 co-mutations may serve as key stratification markers for predicting the potential benefit of immunotherapy in SMARCA4-mutant NSCLC.

24 October 2024 in IEEE Transactions on Artificial Intelligence
Verified
Journal Article
Closed access
JAJinapeng An
Jinapeng An
WLWenqi Li
Wenqi Li
YBYunhao Bai
Yunhao Bai
HCHuazhen Chen
Huazhen Chen
GZGang Zhao
Gang Zhao
ZGZhongke Gao
Zhongke Gao
In the field of esophageal cancer diagnostics, the accurate identification and classification of tumors and adjacent tissues within Whole Slide Images (WSIs) are critical. However, this task is complicated by the difficulty in annotating normal tissue on tumor-bearing slides, as the infiltration results in a blend of different tissue types, making annotation difficult for pathologists. To overcome this challenge, we introduce the Multi- Task Esophageal Cancer Classification (MTECC) framework, featuring an innovative dual-branch architecture that operates at both global and local levels. The framework initially employs a Masked Autoencoder (MAE) for self-supervised learning. A distinctive feature of MTECC is the integration of RandoMix, an innovative image augmentation technique that randomly exchanges patches between different images. This method significantly enhances the model’s generalization ability, especially for recognizing tissues within cancerous slides. MTECC ingeniously integrates two tasks: tumor detection using global tokens, and fine-grained tissue classification at the patch level using local tokens. The empirical evaluation of the MTECC on our extensive esophageal cancer dataset substantiates its efficacy. The performance metrics indicate robust results, with an accuracy of 0.811, an F1 score of 0.735, and an AUC of 0.957. The MTECC method represents a significant advancement in applying deep learning to complex pathological image analysis, offering valuable tools for pathologists in diagnosing and treating esophageal cancer.